1. Завьялов Е.Л., Разумов И.А., Герлинская Л.А., Ромащенко А.В. In vivo МРТ-визуализация динамики развития глиобластомы U87 в модели ортотопической ксенотрансплантации мышам линии SCID. Вавиловский журнал генетики и селекции. 2015; 19(4):460-465. https://doi.org/10.18699/J15.061.
2. Caruso G., Caffo M., Alafaci C., Raudino G., Cafarella D., Lucerna S., Salpietro F.M., Tomasello F. Could nanoparticle systems have a role in the treatment of cerebral gliomas? Nanomedicine. 2011;7(6):744752. https://doi.org/10.1016/j.nano.2011.02.008.
3. Claes A., Idema A.J., Wesseling P. Diffuse glioma growth: a guerilla war. Acta Neuropathol. 2007;114(5):443-458. https://doi.org/10.1007/s00401007-0293-7.
4. Hernandez-Pedro N.Y., Rangel-Lopez E., Magana-Maldonado R., de la Cruz V.P., del Angel A.S., Pineda B., Sotelo J. Application of nanoparticles on diagnosis and therapy in gliomas. Biomed. Res. Int. 2013;351031:1-20. https://doi.org/10.1155/2013/351031.
5. Kuper K.E., Zavjalov E.L., Razumov I.А., Romaschenko A.V., Stupak A.S., Troicky S.Yu., Goldenberg B.G., Legkodymov А.G., Lemzyakov A.A., Moshkin M.P. Cytopathic effects of X-ray irradiation and MnO nanoparticles on human glioblastoma (U87). Physics Procedia. 2016;84:252-255. https://doi.org/10.1016/j.phpro.2016.11.043.
6. Landgraf L., Muller I., Ernst P., Schafer M., Rosman C., Schick I., Kohler O., Oehring H., Breus V.V., Basche T., Sönnichsen C., Treme W., Hilger I. Comparative evaluation of the impact on endothelial cells induced by different nanoparticle structures and functionalization. Beilstein J. Nanotechnol. 2015;6:300-312. https://doi.org/10.3762/bjnano.6.28.
7. Lenting K., Verhaak R., Ter Laan M., Wesseling P., Leenders W. Glioma: Experimental models and reality. Acta Neuropathol. 2017; 133(2):263-282. https://doi.org/10.1007/s00401-017-1671-4.
8. Louis D.N., Perry A., Reifenberger G., von Deimling A., FigarellaBranger D., Cavenee W.K., Ohgaki H., Wiestler O.D., Kleihues P., Ellison D.W. The 2016 World Health Organization classification of tumors of the central nervous system: A summary. Acta Neuropathol. 2016;131(6):803-820. https://doi.org/10.1007/s00401-016-1545-1.
9. Naidu M.D., Mason J.M., Pica R.V., Fung H., Pena L.A. Radiation resistance in glioma cells determined by DNA damage repair activity of Ape1/Ref-1. J. Radiat. Res. 2010;51(4):393-404. https://doi.org/10.1269/jrr.09077.
10. Oh N., Park J.H. Endocytosis and exocytosis of nanoparticles in mammalian cells. Int. J. Nanomedicine. 2014;9(1):51-63. https://doi.org/10.2147/IJN.S26592.
11. Pavlova N.N., Thompson C.B. The emerging hallmarks of cancer metabolism. Cell Metab. 2016;23(1):27-47. https://doi.org/10.1016/j.cmet.2015. 12.006.
12. Poteet E., Choudhury G.R., Winters A., Li W., Ryou M.G., Liu R., Tang L., Ghorpade A., Wen Y., Yuan F., Keir S.T., Yan H., Bigner D.D., Simpkins J.W., Yang S.H. Reversing the Warburg effect as a treatment for glioblastoma. J. Biol. Chem. 2013;288(13):91539164. https://doi.org/10.1074/jbc.AAC118.005625.
13. Razumov I.A., Zavjalov E.L.,Troitskii S.Y.,Romashchenko A.V., Petrovskii D.V., Kuper K.E., Moshkin M.P. Selective cytotoxicity of manganese nanoparticles against human glioblastoma cells. Bull. Exp. Biol. Med. 2017;163(4):561-565. https://doi.org/10.1007/s10517-017-3849-0.
14. Sarkaria J.N., Kitange G.J., James C.D., Plummer R., Calvert H., Weller M., Wick W. Mechanisms of chemoresistance to alkylating agents in malignant glioma. Clin. Cancer Res. 2008;14(10):29002908. https://doi.org/10.1158/1078-0432.CCR-07-1719.
15. Steichen S.D., Caldorera-Moore M., Peppas N.A. A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics. Eur. J. Pharm. Sci. 2013;48(3):416-427. https://doi.org/10.1016/j.ejps.2012.12.006.
16. Stupp R., Hegi M.E., Mason W.P., van den Bent M.J., Taphoorn M.J., Janzer R.C., Ludwin S.K., Allgeier A., Fisher B., Belanger K., Hau P., Brandes A.A., Gijtenbeek J., Marosi C., Vecht C.J., Mokhtari K., Wesseling P., Villa S., Eisenhauer E., Gorlia T., Weller M., Lacombe D., Cairncross J.G., Mirimanoff R.O. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459-466. https://doi.org/10.1016/S1470-2045(09)70025-7.
17. Tran S., DeGiovanni P.J., Piel B., Rai P. Cancer nanomedicine:Areview of recent success in drug delivery. Clin. Transl. Med. 2017;6(1):44. https://doi.org/10.1186/s40169-017-0175-0.
18. Tzeng S.Y., Green J.J. Therapeutic nanomedicine for brain cancer. Ther. Deliv. 2013;4(6):687-704. https://doi.org/10.4155/tde.13.38.
19. Vinardell M.P., Mitjans M. Antitumor activities of metal oxide nanoparticles. Nanomaterials (Basel). 2015;5(2):1004-1021. https://doi.org/10.3390/nano5021004.
20. Warburg O., Wind F., Negelein E. The metabolism of tumors in the body. J. Gen. Physiol. 1927;8(6):519-530.